We explore how family offices are shifting from passive LPs to active backers of early-stage biotechnology. With venture capital drying up for clinical-stage companies, independent wealth managers are filling the gap by funding direct investments in genomics and personalized medicine. We look at the specific mechanics of these deals, the higher risk tolerance required, and what this means for the future of medical innovation as we move through Q4 2026.
#FexingoBusiness #BusinessPodcast #FamilyOffice #BiotechInvesting #VentureCapital #PrivateEquity #HealthcareInnovation #Genomics #ClinicalTrials #RiskManagement #MedicalBreakthroughs #InvestmentStrategy #LongTermCapital #StartupFunding #Pharmaceuticals #LifeSciences #LucasAndLuna #WealthManagement
<a href="https://buymeacoffee.com/fexingo">Keep every episode free: buymeacoffee.com/fexingo</a>

We explore how family offices are shifting from passive LPs to active backers of early-stage biotechnology. With venture capital drying up for clinical-stage companies, independent wealth managers are filling the gap by funding direct investments in genomics and personalized medicine. We look at the specific mechanics of these deals, the higher risk tolerance required, and what this means for the future of medical innovation as we move through Q4 2026.

#FexingoBusiness #BusinessPodcast #FamilyOffice #BiotechInvesting #VentureCapital #PrivateEquity #HealthcareInnovation #Genomics #ClinicalTrials #RiskManagement #MedicalBreakthroughs #InvestmentStrategy #LongTermCapital #StartupFunding #Pharmaceuticals #LifeSciences #LucasAndLuna #WealthManagement

Keep every episode free: <a href="https://buymeacoffee.com/fexingo">buymeacoffee.com/fexingo</a>

We explore how family offices are shifting from passive LPs to active backers of early-stage biotechnology. With venture capital drying up for clinical-stage companies, independent wealth managers are filling the gap by funding direct investments in...

Family Offices Funding Biotech Startups

Description